Hikma Pharmaceuticals (LON:HIK – Get Rating)‘s stock had its “overweight” rating reaffirmed by stock analysts at Barclays in a note issued to investors on Monday, MarketBeat Ratings reports. They presently have a GBX 2,800 ($34.98) price target on the stock. Barclays‘s price objective points to a potential upside of 64.67% from the stock’s previous close.
Several other brokerages have also recently weighed in on HIK. Morgan Stanley cut shares of Hikma Pharmaceuticals to an “equal weight” rating and dropped their price target for the company from GBX 2,800 ($34.98) to GBX 2,300 ($28.73) in a research report on Thursday, March 3rd. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Hikma Pharmaceuticals in a research note on Monday, January 17th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Hikma Pharmaceuticals currently has an average rating of “Buy” and an average target price of GBX 2,585 ($32.29).
Shares of Hikma Pharmaceuticals stock opened at GBX 1,700.38 ($21.24) on Monday. The stock has a market capitalization of £3.84 billion and a P/E ratio of 11.85. Hikma Pharmaceuticals has a one year low of GBX 1,651.50 ($20.63) and a one year high of GBX 2,703 ($33.77). The company has a debt-to-equity ratio of 34.29, a current ratio of 2.06 and a quick ratio of 1.31. The business’s 50 day simple moving average is GBX 2,005.70 and its two-hundred day simple moving average is GBX 2,120.08.
About Hikma Pharmaceuticals (Get Rating)
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded.
- ChemoCentryx: A Biotech Stock Well Worth the Risk
- Skechers Stock Can Be Bought on Pullbacks
- Nasdaq Stock is a Buy the (Deep) Dip Opportunity
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.